# US 2021/0063402 A1 · Screening method, device and kit for detecting mucosal carbohydrates and associated conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0063402 A1
- Document ID: US20210063402A1
- Status: Published application
- Kind: A1
- Application number: 16/937,051
- Filed: 2020-07-23
- Published: 2021-03-04
- Earliest claimed: 2019-08-29
- Inventors: AbulKalam Mohammed Shamsuddin
- Web page: https://patentgrep.com/patent/US20210063402A1

## CPC

- G01N 33/5756: {involving tumour-associated glycolinkage [TAG]}
- C12Q 1/26: involving oxidoreductase
- G01N 33/487: of liquid biological material
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/64: involving ketones
- G01N 2333/904: acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
- G01N 2400/00: Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N 2400/38: Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This disclosure relates to a screening test method, device, and kit for mucosal carbohydrates and associated conditions including, cancerous and precancerous conditions. Specifically, the method tests abnormal carbohydrates in mucus or body fluid using reagents of galactose oxidase, and Schiff's Reagent. The screening test method, device, and kit provides improved accuracy, and minimizes handling procedures. This disclosure further relates to the use of the device or kit in a medical facility for an initial evaluation for cancerous and precancerous conditions.

## Claims

### Claim 1

A screening device for rapidly testing a human being for expression of a mucosal carbohydrate comprising
a test strip or membrane with galactose oxidase pre-embedded, and
a container with Schiff reagent solution,
wherein the Schiff reagent solution is not initially in contact with the test strip or membrane, and the Schiff reagent solution can be activated to contact the test strip or membrane after marker carbohydrates are oxidized by galactose oxidase.

### Claim 2

A screening device for rapidly testing a human being for a cancerous or precancerous condition comprising
a test strip or membrane with galactose oxidase pre-embedded, and
a container with Schiff reagent solution,
wherein the Schiff reagent solution is not initially in contact with the test strip or membrane, and the Schiff reagent solution can be activated to contact the test strip or membrane after marker carbohydrates are oxidized by galactose oxidase.

### Claim 3 (depends on 1)

The screening device according to claim 1, wherein the galactose oxidase is microencapsulated.

### Claim 4 (depends on 1)

The screening device according to claim 1, the test strip or membrane further contains dry culture medium, wherein the dry culture medium can activate the galactose oxidase once water is added onto the test strip or membrane.

### Claim 5 (depends on 1)

The screening device according to claim 1, wherein the Schiff reagent solution is activated by opening a twist valve or by breaking a barrier between the Schiff reagent solution container and the test strip or membrane.

### Claim 6 (depends on 1)

The screening device according to claim 1, wherein the Schiff reagent solution is a storage-stable Schiff reagent solution.

### Claim 7

A screening method for rapidly testing a human being for expression of a mucosal carbohydrate comprising:
applying mucus or body fluid to a test strip or membrane with galactose oxidase pre-embedded,
oxidizing marker carbohydrates in the mucus or body fluid by reacting with galactose oxidase, and
activating a container with Schiff reagent solution adjacent to the test strip or membrane to contact the test strip or membrane,
wherein the Schiff reagent solution is not initially in contact with the test strip or membrane.

### Claim 8

A screening method for rapidly testing a human being for a cancerous or precancerous condition comprising
applying mucus or body fluid to a test strip or membrane with galactose oxidase pre-embedded,
oxidizing marker carbohydrates in the mucus or body fluid by reacting with galactose oxidase, and
activating a container with Schiff reagent solution adjacent to the test strip or membrane to contact the test strip or membrane,
wherein the mucus or body fluid contains marker carbohydrates;
the Schiff reagent solution is not initially in contact with the test strip or membrane.

### Claim 9 (depends on 7)

The screening method according to claim 7 further comprising applying water onto the test strip or membrane before applying mucus or body fluid to the test strip or membrane.

### Claim 10 (depends on 7)

The screening method according to claim 7, wherein the galactose oxidase is microencapsulated.

### Claim 11 (depends on 7)

The screening method according to claim 7, wherein the test strip or membrane further contains dry culture medium, and the dry culture medium can activate the galactose oxidase once water is added onto the test strip or membrane.

### Claim 12 (depends on 11)

The screening method according to claim 11, further comprising applying water onto the test strip or membrane before applying mucus or body fluid to the test strip or membrane.

### Claim 13 (depends on 7)

The screening method according to claim 7, wherein activating the container with Schiff reagent solution adjacent to the test strip or membrane through opening a twist valve or breaking a barrier between the Schiff reagent solution container and the test strip or membrane.

### Claim 14 (depends on 7)

The screening method according to claim 7, wherein oxidizing marker carbohydrates in the mucus or body fluid by reacting with galactose oxidase for a period of 5 to 20 minutes.

### Claim 15 (depends on 7)

The screening method according to claim 7, further comprising removing the mucus or body fluid by washing before activating a container with Schiff reagent solution.

### Claim 16 (depends on 7)

The screening method according to claim 7, further comprising letting the Schiff reagent solution to contact the test strip or membrane for a period of 0.5 to 5 mins.

### Claim 17 (depends on 16)

The screening method according to claim 16, further comprising washing the test strip or membrane with tap water after letting the Schiff reagent solution to contact the test strip or membrane for a period of 0.5 to 5 mins, drying the test strip or membrane, and evaluating color of the test strip or membrane.

### Claim 18

A screening kit for rapidly testing a human being for expression of a mucosal carbohydrate comprising
a test strip or membrane with galactose oxidase pre-embedded, and
a container with Schiff reagent solution.

### Claim 19

A screening kit for rapidly testing a human being for a cancerous or precancerous condition comprising
a test strip or membrane with galactose oxidase pre-embedded, and
a container with Schiff reagent solution.

### Claim 20 (depends on 18)

The screening kit according to claim 18, wherein the galactose oxidase is microencapsulated.

### Claim 21 (depends on 18)

The screening kit according to claim 18, wherein the test strip or membrane further contains dry culture medium, wherein the dry culture medium can activate the galactose oxidase once water is added onto the test strip or membrane.

### Claim 22 (depends on 2)

The use of the screening device according to claim 2 to screen a cancerous or precancerous condition.

### Claim 23 (depends on 22)

The use of the screening device according to claim 22, wherein the cancerous or precancerous condition is rectal, colon, blood, lymph node, stomach, kidney, gall bladder, prostate, testes, breast, cervix, or ovaries cancerous or precancerous condition.

### Claim 24 (depends on 19)

The use of the screening kit according to claim 19 to screen a cancerous or precancerous condition.
